Ocusphere Therapeutics Inc

Ocusphere have raised a total of 1.2M USD in funding from our co-founder and angel investor, Mr. Huang, to support the development of our company and its mission. OcuSphere Therapeutics is a startup-stage gene therapy company focused on creating an AI-powered, modularized platform to produce affordable, non-viral based genetic medicines for patients with inherited retinal diseases and neurodegenerative conditions. Our aim is to discover, manufacture, and commercialize durable, effective gene therapies that are accessible to all patients worldwide. We are driven by the belief that genetic medicines should be affordable for every patient. The current cost of gene therapy, priced at 850,000 USD, poses a significant challenge for many. With our cutting-edge technology, developed in the laboratory of the Institute of Ophthalmology, University College London, we are committed to disrupting the current gene therapy market and making life-changing treatments accessible to those in need.